At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Oral Tablet: Cabozantinibdrug
Likely dose
Oral Tablet: Cabozantinib 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Academic Thoracic Oncology Medical Investigators Consortium·interventional·Posted May 31, 2018·Updated Jul 15, 2022
In Brief
A Phase 2 clinical trial evaluating Oral Tablet: Cabozantinib for Colorectal Cancer. Completed, enrolled 44 participants across 10 sites.
Detailed Summary
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
CollaboratorsUniversity of Colorado, Denver
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionOct 2020
Study CompletionMar 2022
TodayJul 2026
First PostedMay 31, 2018
Enrollment StartJun 1, 2018
Primary CompletionOct 19, 2020
Study CompletionMar 7, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.1 years ago
Interventions
Oral Tablet: Cabozantinibdrug
Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.